Endo International Overview

  • Year Founded
  • 1935

Year Founded

  • Status
  • Public

  • Employees
  • 2,931

Employees

  • Stock Symbol
  • ENDPQ

Stock Symbol

  • Investments
  • 24

Endo International General Information

Description

Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, orthopedics, endocrinology, bariatrics, and others. It operates in four segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. The company generates maximum revenue from the Branded Pharmaceuticals segment. Some of its products include XIAFLEX, SUPPRELIN, PERCOCET, TESTOPEL, VASOSTRICT, ADRENALIN, and APLISOL.

Contact Information

Website
www.endo.com
Formerly Known As
Endo Laboratories
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
PINX
Corporate Office
  • First Floor, Minerva House
  • Simmonscourt Road, Ballsbridge
  • Dublin
  • Ireland
+353 (01) 000 0000

Endo International Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Endo International Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$70.6K 235M 94.9K -$10.42

Endo International Financials Summary

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 6,571,320 6,571,320 (1,032,153) 7,630,333
Revenue 2,011,518 2,011,518 2,318,875 2,993,206
EBITDA (2,085,476) (2,085,476) (2,146,697) 472,848
Net Income (2,449,807) (2,449,807) (2,923,105) (613,245)
Total Assets 5,137,294 5,137,294 5,757,937 8,767,415
Total Debt 5,088 5,088 6,032 8,294,041
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Endo International Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Endo International‘s full profile, request access.

Request a free trial

Endo International Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Endo International PLC is a specialty pharmaceutical company with a considerable presence in pain management, urology, o
Pharmaceuticals
Dublin, Ireland
2,931 As of 2023
00.00
000000000 00.00

0000 0

is nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
000000000000000
Petah Tikva, Israel
00000 As of 0000
000.00
000000000 00 000.00

00000

ectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore ma
000000000000000
Basel, Switzerland
000000 As of 0000
000.00
000000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Endo International Competitors (14)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Teva Pharmaceutical Industries Corporate Backed or Acquired Petah Tikva, Israel 00000 000.00 000000000 00 000.00
Roche Corporation Basel, Switzerland 000000 000.00 000000000000 000.00
Novartis India Corporate Backed or Acquired Mumbai, India 00 00.000 0&0
Aurobindo Pharma Corporation Hyderabad, India 00000 00000 000000000 00000
AstraZeneca Formerly PE-Backed Cambridge, United Kingdom 00000 000.00 000000000 00 000.00
You’re viewing 5 of 14 competitors. Get the full list »

Endo International Patents

Endo International Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20160000061-A1 Game tracking device Active 03-Jul-2014 0000000000 00
US-10285396-B2 Game tracking device Active 03-Jul-2014 0000000000 00
CA-2905721-A1 Urethral anastomosis device Inactive 14-Mar-2013 000000000
US-20180030026-A1 Inhibitors of the kynurenine pathway Active 14-Mar-2013 0000000000
US-10294212-B2 Inhibitors of the kynurenine pathway Active 14-Mar-2013 C07D333/66 0
To view Endo International’s complete patent history, request access »

Endo International Executive Team (34)

Name Title Board Seat Contact Info
Blaise Coleman President, Chief Executive Officer & Board Member
Patrick Barry Executive Vice President & President Global Commercial Operations
Mark Bradley Executive Vice President & Chief Financial Officer
Frank Raciti Chief Accounting Officer, Accounting & Controller, Finance
Susan Williamson Senior Vice President & Chief Compliance Officer
You’re viewing 5 of 34 executive team members. Get the full list »

Endo International Board Members (14)

Name Representing Role Since
000000 0000000 Endo International President, Chief Executive Officer & Board Member 000 0000
00000000 0000 Self Board Member 000 0000
0000 00000000 Endo International Chairman & Board Member 000 0000
0000 00000 00.0 Endo International Board Member 000 0000
0000000 00000 Endo International Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Endo International Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Endo International Investments & Acquisitions (24)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Nevakar Injectables (Six Development Stage -Injectable Product) 09-May-2022 000000000 0000 Buildings and Property
Biospecifics Technologies 01-Dec-2020 0000000000 00000 Pharmaceuticals 000000 00
Somerset Pharma 26-Apr-2018 0000000000 00000 Pharmaceuticals 0000 0000
Aspen Holdings (branded and generic injectable and established products) 01-Oct-2015 0000000000 00000 Medical Supplies
Par Pharmaceutical Companies 25-Sep-2015 Merger/Acquisition 00.000 Pharmaceuticals
You’re viewing 5 of 24 investments and acquisitions. Get the full list »

Endo International Subsidiaries (4)

Company Name Industry Location Founded
Auxilium Pharmaceuticals Pharmaceuticals Chesterbrook, PA 1999
Nascobal Pharmaceuticals Bothell, WA 0000
Paladin Labs Pharmaceuticals Saint-Laurent, Canada 0000
Par Pharmaceutical Companies Pharmaceuticals Ramapo, NY 0000
To view Endo International’s complete subsidiaries history, request access »

Endo International ESG

Risk Overview

Risk Rating

Updated December, 21, 2023

38.85 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,173

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 909

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 444

Rank

00.00

Percentile

To view Endo International’s complete esg history, request access »

Endo International Exits (6)

Company Name Exit Date Exit Type Exit Size Status Buyers
Par Pharmaceutical Companies 25-Sep-2015 000000000000000000 00.000 Completed
  • 0000 0000000000000
Grupo Farmaceutico Somar 24-Jul-2014 000000000000000000 00000 Completed
  • 0000 0000000000000
American Medical Systems 11-Apr-2011 000000000000000000 00.00 Completed
  • 0000 0000000000000
HealthTronics 15-Jul-2010 000000000000000000 00000 Completed
  • 0000 0000000000000
Endo Pharmaceuticals Solutions 05-Jan-2009 Merger/Acquisition 00000 Completed
You’re viewing 5 of 6 exits. Get the full list »

Endo International FAQs

  • When was Endo International founded?

    Endo International was founded in 1935.

  • Who is the CEO of Endo International?

    Blaise Coleman is the CEO of Endo International.

  • Where is Endo International headquartered?

    Endo International is headquartered in Dublin, Ireland.

  • What is the size of Endo International?

    Endo International has 2,931 total employees.

  • What industry is Endo International in?

    Endo International’s primary industry is Pharmaceuticals.

  • Is Endo International a private or public company?

    Endo International is a Public company.

  • What is Endo International’s stock symbol?

    The ticker symbol for Endo International is ENDPQ.

  • What is the current market cap of Endo International?

    The current market capitalization of Endo International is $70.6K.

  • What is Endo International’s current revenue?

    The trailing twelve month revenue for Endo International is $2.01B.

  • Who are Endo International’s competitors?

    Teva Pharmaceutical Industries, Roche, Novartis India, Aurobindo Pharma, and AstraZeneca are some of the 14 competitors of Endo International.

  • What is Endo International’s annual earnings per share (EPS)?

    Endo International’s EPS for 12 months was -$10.42.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »